BioSpace News Archive

Business

Zura Bio Announces Robert Lisicki as CEO and Director

Zura Bio Limited a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, announced that Robert Lisicki has assumed the role of Chief Executive Officer and a Director of the Board at Zura Bio.

April 8, 2024
·
7 min read
Genetown

Boston Scientific Initiates NAVIGATE-PF Study of the FARAWAVE™ Nav Pulsed Field Ablation Catheter and FARAVIEW™ Software Module

Boston Scientific Corporation has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize and track the FARAWAVE™ Nav Pulsed Field Ablation Catheter* for the treatment of patients with paroxysmal and persistent atrial fibrillation.

April 8, 2024
·
5 min read
Pharm Country

ViroCell to present at 2024 Cell & Gene Meeting on the Med

ViroCell Biologics announces that John W. Hadden II, Chief Executive Officer, will be presenting at the annual Cell & Gene Meeting on the Med to be held April 9-11 in Rome, Italy.

April 8, 2024
·
3 min read
Business

OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann

OMass Therapeutics, a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, announces the appointment of Sarah Teichmann PhD, FMedSci, FRS to its Scientific Advisory Board, effective immediately.

April 8, 2024
·
3 min read
Drug Development

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

Zymeworks Inc. announced five presentations including new data from its preclinical development-stage programs at the 2024 American Association for Cancer Research Annual Meeting being held in San Diego, California April 5-10, 2024.

April 8, 2024
·
12 min read
Drug Development

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Shanghai Henlius Biotech, Inc. and Organon announced that the phase 3 comparative clinical trial for the investigational Prolia® and Xgeva® biosimilar HLX14 met the primary endpoints.

April 8, 2024
·
7 min read
Drug Development

Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Oculis Holding AG announced that Eric Donnenfeld, M.D., presented the positive results from the Phase 3 OPTIMIZE-1 trial of OCS-01 for the treatment of inflammation and pain following cataract surgery at the 2024 ASCRS Annual Meeting, which took place April 5-8, 2024, in Boston, MA.

April 8, 2024
·
7 min read
Pharm Country

TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy.

April 8, 2024
·
2 min read
Business

Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024

Organon, a global healthcare company with a focus on women’s health, will release its first quarter 2024 financial results on May 2, 2024, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.

April 8, 2024
·
4 min read
Genetown

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”) today announced preclinical data on zenocutuzumab (Zeno) in cancer models with high neuregulin 1 (NRG1) expression were presented at the American Association of Cancer Research (AACR) Annual Meeting 2024.

April 8, 2024
·
6 min read